via Benigno Crespi 17 Milano 20159 Italy [t] 0039-02-69969711-509
The Sorin Group is a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases.
The Sorin Group features the following brands: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia.
At the Sorin Group 4,500 employees serve over 5,000 public and private treatment centres in more than 80 countries.
Sorin Group receives FDA approval for the SMARTVIEW remote monitoring solution for patients with implanted cardiac rhythm management (CRM) devices and the company is beginning the US launch of the device.
Sorin Group receives US Food and Drug Administration (FDA) approval of the company's Investigational Device Exemption (IDE) application and clinical trial protocol to begin evaluating its PERCEVAL S sutureless aortic tissue valve.
Sorin Group receives US Food and Drug Administration (FDA) conditional approval for the company's Investigational Device Exemption (IDE) application and clinical trial protocol for RESPOND CRT.
Sorin Group makes an additional minority investment linked with an option-to-buy in Enopace Biomedical, an early-stage company focused on the development of a neuromodulation system to treat patients with Heart Failure.
Sorin Group receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval for the company's Mitroflow Aortic Pericardial Heart Valve.
Sorin Group launching the Mitroflow Valsalva Conduit in the USA, which claims to be the only Valsalva conduit graft approved by the US Food and Drug Administration (FDA) for use in combination with an aortic tissue valve.
Sorin Group receives marketing approval from China's State Food and Drug Administration (SFDA) and full commercial launch in China of the REPLY and ESPRIT families of pacemakers.
Sorin Group is making a minority investment in Cardiosolutions, an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation.
The Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, is deploying Camstar Systems' Camstar Enterprise Platform to support its global growth and continuous improvement initiatives.
Sorin Group and Orange Business Services, a leading global communications solutions integrator, are launching SMARTVIEW, a remote monitoring solution for patients with implanted cardiac rhythm management(CRM) devices in several countries in Europe.
Sorin Group is reporting the first patient enrolment in the DREAM clinical trial which is a study is to evaluate sensitivity and positive
predictive value of Sleep Apnea Monitoring (SAM) in pacemaker patients, compared to polysomnography, the gold standard test to diagnose sleep apnea disorders.
Sorin Group receives authorization from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to market its MEMO 3D Semi-Rigid Annuloplasty Ring.
Sorin Group receives CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Designed for safety and long term reliability, TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families offer multiple implant options to accommodate patients' needs and physicians' preferences.
Sorin Group is making a minority investment in Enopace Biomedical, an early-stage company focused on the development of a neuromodulation system to treat patients with congestive heart failure.
Sorin Group reaches a major milestone with more than 100,000 of the company’s Mitroflow Aortic Pericardial Heart Valves having now been implanted worldwide.
Sorin Group enters into a distribution agreement with CardioMedical, making Sorin Group, CardioMedical’s selected partner for the entire Cardio Vision MIS Portfolio which is a comprehensive catalogue of minimally invasive cardiac surgery instruments and accessories.
Sorin Group receives US FDA approval and completes first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym CRT Model 8750.
Sorin Group reports the first inclusion of a patient in the Clepsydra clinical trial which will investigate the sensitivity to changes in heart failure status of PhD, a diagnostic feature using the dual sensor technology of minute ventilation and accelerometer to monitor patient’s breathing and activity levels every day.
Orange Business Services and Sorin Group are named ′Best Change-Maker’ at this year’s annual World Communication Awards (WCA) for their innovative work in the development of a remote monitoring solution for cardiac patients.
Sorin Group receives the Health Canada Therapeutic Products Directorate (TPD) approval to market the REPLY family of dual and single chamber rate adaptive pacemakers.
Japan’s Ministry of Health, Labor and Welfare (MHLW) gives approval to market the Facil and Reply families of dual and single chamber rate responsive pacemakers.
Sorin Group delivers its 1000th S5 Heart-Lung Machine with a contract to supply the Mount Sinai Medical Center, one of the world’s leading centres for cardiovascular medicine, based in New York, USA.
Sorin Group is entering into a long-term exclusive distribution agreement with Japan Lifeline (JLL), a leading distributor of medical devices in Japan.
Sorin Group together with Orange Business Services, the leading global communications solutions integrator, are planning to develop and service a remote monitoring solution for patients implanted with cardiac rhythm management (CRM) devices.
Sorin Group has enrolled the first three patients in a clinical trial aimed at obtaining European market approval for the company’s ′Perceval S’ Sutureless Aortic Heart Valve.
Sorin Group has acquired the Clearglide endoscopic vessel harvesting product line of Datascope. Endoscopic vessel harvesting (′EVH’) devices enable less-invasive harvesting of vessels for use in coronary artery bypass grafting.
Sorin Group has completed the divestment of its Renal Care Business to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, on behalf of the closed-end fund ′Emilia Venture’.
Sorin Group has released its new-generation Paradym CRT 8750 cardiac resynchronization therapy defibrillator (CRT-D) and completed the device's first implant.
Sorin Group has received an offer for the acquisition of its renal care business and the group has granted exclusivity to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, for the purpose of finalising negotiations.
Sorin Group has announced the first patient enrolment in the e-Optima registry which is designed to assess the clinical performance of the Sorin Group Optima Drug-Eluting Stent (DES) Carbostent in the treatment of real-world patients in routine clinical practice.
A report detailing 21-year durability data of Sorin’s Mitroflow Aortic Pericardial Heart Valve has been published in the September issue of the Journal Of Thoracic And Cardiovascular Surgery.
Sorin Group has divested its peripheral stent business to Datascope, which has become the new owner of the entire Sorin peripheral vascular stent product business worldwide.
The Sorin Group and Greatbatch is to collaborate to enable Greatbatch's eM-able technology to be use in the Sorin Group's future cardiac rhythm management (CRM) systems.
